Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals

OBJECTIVE: To describe and evaluate empiric antimicrobial regimens chosen for hospitalized patients with presumed community-acquired pneumonia (CAP) in US hospitals, including compliance with the American Thoracic Society (ATS) guidelines. Secondary outcomes included length of stay (LOS) and mortality associated with the choice of therapy. METHODS: A nonrandomized, prospective, observational study was performed in 72 nonteaching hospitals affiliated with a national group purchasing organization. Patients with an admission diagnosis of physician-presumed CAP and an X-ray taken within 72 hours of admission were eligible for the study. Demographic, antibiotic selection, and outcomes data were collected prospectively from patient charts. RESULTS: 3035 patients were enrolled; 2963 were eligible for analysis. Compliance with the ATS guidelines was 81% in patients with nonsevere CAP. The most common antibiotic regimen used for empiric treatment was ceftriaxone alone or in combination with a macrolide (42%). The overall mortality rate was 5.5%. The addition of a macrolide to either a second- or third-generation cephalosporin or a beta-lactam/beta-lactamase inhibitor was associated with decreased mortality and reduced LOS. CONCLUSIONS: Most hospitalized patients with CAP receive antimicrobial therapy consistent with the ATS guidelines. The addition of a macrolide may be associated with improved patient outcomes.

This article has been cited by other articles:

				T. P. Lodise, A. Kwa, L. Cosler, R. Gupta, and R. P. Smith Comparison of {beta}-Lactam and Macrolide Combination Therapy versus Fluoroquinolone Monotherapy in Hospitalized Veterans Affairs Patients with Community-Acquired Pneumonia Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3977 - 3982. [Abstract] [Full Text] [PDF]

				R. Menendez and A. Torres Treatment Failure in Community-Acquired Pneumonia Chest, October 1, 2007; 132(4): 1348 - 1355. [Abstract] [Full Text] [PDF]

				M. Paul, A. D. Nielsen, A. Gafter-Gvili, E. Tacconelli, S. Andreassen, N. Almanasreh, E. Goldberg, R. Cauda, U. Frank, L. Leibovici, et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis Eur. Respir. J., September 1, 2007; 30(3): 525 - 531. [Abstract] [Full Text] [PDF]

				F. W. Arnold, J. T. Summersgill, A. S. LaJoie, P. Peyrani, T. J. Marrie, P. Rossi, F. Blasi, P. Fernandez, T. M. File Jr., J. Rello, et al. A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia Am. J. Respir. Crit. Care Med., May 15, 2007; 175(10): 1086 - 1093. [Abstract] [Full Text] [PDF]

				G. P. Samsa, D. B. Matchar, J. Harnett, and J. Wilson A Cost-Minimization Analysis Comparing Azithromycin-Based and Levofloxacin-Based Protocols for the Treatment of Patients Hospitalized With Community-Acquired Pneumonia: Results From the CAP-IN Trial Chest, November 1, 2005; 128(5): 3246 - 3254. [Abstract] [Full Text] [PDF]

				D. Aujesky and M. J. Fine Does Guideline Adherence for Empiric Antibiotic Therapy Reduce Mortality in Community-acquired Pneumonia? Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 655 - 656. [Full Text] [PDF]

				R. Menendez, A. Torres, R. Zalacain, J. Aspa, J. J. Martin-Villasclaras, L. Borderias, J. M. Benitez-Moya, J. Ruiz-Manzano, F. R. de Castro, J. Blanquer, et al. Guidelines for the Treatment of Community-acquired Pneumonia: Predictors of Adherence and Outcome Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 757 - 762. [Abstract] [Full Text] [PDF]

				R Menendez, A Torres, R Zalacain, J Aspa, J J Martin Villasclaras, L Borderias, J M Benitez Moya, J Ruiz-Manzano, F Rodriguez de Castro, J Blanquer, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome Thorax, November 1, 2004; 59(11): 960 - 965. [Abstract] [Full Text] [PDF]

				F. Blasi Atypical pathogens and respiratory tract infections Eur. Respir. J., July 1, 2004; 24(1): 171 - 182. [Abstract] [Full Text] [PDF]

				T. M. File Jr, J. Garau, F. Blasi, C. Chidiac, K. Klugman, H. Lode, J. R. Lonks, L. Mandell, J. Ramirez, and V. Yu Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia Chest, May 1, 2004; 125(5): 1888 - 1901. [Abstract] [Full Text] [PDF]

				R. Menendez, M.J. Cremades, E. Martinez-Moragon, J.J. Soler, S. Reyes, and M. Perpina Duration of length of stay in pneumonia: influence of clinical factors and hospital type Eur. Respir. J., October 1, 2003; 22(4): 643 - 648. [Abstract] [Full Text] [PDF]

				J. J. Oosterheert, M. J. M. Bonten, E. Buskens, M. M. E. Schneider, and I. M. Hoepelman Algorithm To Determine Cost Savings of Targeting Antimicrobial Therapy Based on Results of Rapid Diagnostic Testing J. Clin. Microbiol., October 1, 2003; 41(10): 4708 - 4713. [Abstract] [Full Text] [PDF]

				J. J. Oosterheert, M. J. M. Bonten, E. Hak, M. M. E. Schneider, and I. M. Hoepelman How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review J. Antimicrob. Chemother., October 1, 2003; 52(4): 555 - 563. [Abstract] [Full Text] [PDF]

				R. B. Brown, P. Iannini, P. Gross, and M. Kunkel Impact of Initial Antibiotic Choice on Clinical Outcomes in Community-Acquired Pneumonia: Analysis of a Hospital Claims-Made Database Chest, May 1, 2003; 123(5): 1503 - 1511. [Abstract] [Full Text] [PDF]

				R. Menendez, D. Ferrando, J. M. Valles, and J. Vallterra Influence of Deviation From Guidelines on the Outcome of Community-Acquired Pneumonia* Chest, August 1, 2002; 122(2): 612 - 617. [Abstract] [Full Text] [PDF]